METTL7B

Across TCGA pan-cancer cohorts, METTL7B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated METTL7B data layer compared with 31 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher METTL7B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated METTL7B expression acts as an unfavorable survival marker.

BLCA, BRCA, and LUAD are the cancer types where METTL7B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.147	0.711	<.001	54	view →
BRCA	OS	Median	All	0.112	0.579	<.001	28	view →
LUAD	OS	Median	All	0.313	0.812	.015	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
HNSC	OS	Median	All	0.183	0.660	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

METTL7B–BLCA (OS)

Open the BLCA breakdown →